These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 17700645)

  • 1. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
    Costa AC; Scott-McKean JJ; Stasko MR
    Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.
    Rueda N; Llorens-Martín M; Flórez J; Valdizán E; Banerjee P; Trejo JL; Martínez-Cué C
    J Alzheimers Dis; 2010; 21(1):277-90. PubMed ID: 20421694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
    Lockrow J; Boger H; Bimonte-Nelson H; Granholm AC
    Behav Brain Res; 2011 Aug; 221(2):610-22. PubMed ID: 20363261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.
    Ahmed MM; Dhanasekaran AR; Block A; Tong S; Costa AC; Stasko M; Gardiner KJ
    PLoS One; 2015; 10(3):e0119491. PubMed ID: 25793384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801.
    Siddiqui A; Lacroix T; Stasko MR; Scott-McKean JJ; Costa AC; Gardiner KJ
    Genes Brain Behav; 2008 Oct; 7(7):810-20. PubMed ID: 19125866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
    Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
    Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.
    Scott-McKean JJ; Costa AC
    Learn Mem; 2011 Dec; 18(12):774-8. PubMed ID: 22101180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1).
    Costa AC; Stasko MR; Schmidt C; Davisson MT
    Behav Brain Res; 2010 Jan; 206(1):52-62. PubMed ID: 19720087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.
    Costa AC
    Dev Neurosci; 2011; 33(5):414-27. PubMed ID: 21893967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
    Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
    J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.
    Scott-McKean JJ; Roque AL; Surewicz K; Johnson MW; Surewicz WK; Costa ACS
    Neural Plast; 2018; 2018():9235796. PubMed ID: 29849573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.
    Boada R; Hutaff-Lee C; Schrader A; Weitzenkamp D; Benke TA; Goldson EJ; Costa AC
    Transl Psychiatry; 2012 Jul; 2(7):e141. PubMed ID: 22806212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease.
    Dong H; Yuede CM; Coughlan C; Lewis B; Csernansky JG
    Neuropsychopharmacology; 2008 Dec; 33(13):3226-36. PubMed ID: 18418360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.
    Hesselink MB; Smolders H; De Boer AG; Breimer DD; Danysz W
    Behav Pharmacol; 1999 Feb; 10(1):85-98. PubMed ID: 10780305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
    Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
    Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine learning methods predict locomotor response to MK-801 in mouse models of down syndrome.
    Nguyen CD; Costa AC; Cios KJ; Gardiner KJ
    J Neurogenet; 2011 Mar; 25(1-2):40-51. PubMed ID: 21391779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a single memantine treatment on behavioral alterations associated with binge alcohol exposure in neonatal rats.
    Idrus NM; McGough NN; Spinetta MJ; Thomas JD; Riley EP
    Neurotoxicol Teratol; 2011; 33(4):444-50. PubMed ID: 21565269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.